Immunomedics, Inc. Release: Lupus Patients Treated With Epratuzumab Report Improvements in Health-Related Quality of Life

Published: Nov 13, 2012

WASHINGTON, Nov. 13, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that patients receiving epratuzumab reported clinically meaningful improvements in health-related quality of life (HRQoL) that were sustained over approximately 4 years of treatment.

Back to news